LETTER
Ni-Catalyzed Cross-Coupling for Synthesis of 4-Substituted Coumarins
2367
Lett. 2002, 43, 9195. (j) Song, A. M.; Wang, X. B.; Lam, K.
S. Tetrahedron Lett. 2003, 44, 1755. (k) Kaye, P. T.; Musa,
M. A. Synth. Commun. 2003, 33, 1755. (l) Pave, G.;
Chalard, P.; Viaud-Massuard, M. C. Synlett 2003, 987.
(m) Fringuelli, F.; Piermatti, O.; Pizzo, F. Synthesis 2003,
2331. (n) Selles, P.; Mueller, U. Org. Lett. 2004, 6, 277.
(o) Kontogiorgis, C. A.; Hadjipavlou-Litina, D. J. Bioorg.
Med. Chem. Lett. 2004, 14, 611.
4-mesylcoumarins to obtain the corresponding coupling
products in moderate to high yields (entries 1, 3–7). 3-
Iodo-6-methoxy-benzopyran-4-one (5k) also reacted with
mesylate 3d to give 83% yield of the corresponding prod-
uct 7h (entry 2).17
In summary, we have demonstrated a new nickel-cata-
lyzed cross-coupling of 4-mesylcoumarins with aryl or vi-
nyl halides in the NiCl2(PPh3)2/PPh3/Zn/toluene reaction
system. A number of useful 4-arylcoumarin compounds
were obtained in good yields under mild conditions. Un-
like the previously reported coupling examples, this new
coupling method avoids the use of toxic organostannanes,
sensitive organozinc reagents and expensive arylboronic
acids; on the contrary, it allows the direct cross-coupling
of easily accessible 4-mesylcoumarins with aryl or vinyl
halides. Furthermore, the functional group such as alde-
hyde is tolerated under the reaction conditions. This has
greatly facilitated the synthesis of a variety of biologically
important 4-substituted coumarins. Application of this
coupling method to construct a library of 4-coumarins is
currently underway.
(4) Kadnikov, D. V.; Larock, R. C. Org. Lett. 2000, 2, 3643.
(5) Boland, G. M.; Donnelly, D. M. X.; Finet, J.-P.; Rea, M. D.
J. Chem. Soc., Perkin Trans. 1 1996, 2591.
(6) Yao, M.-L.; Deng, M.-Z. Heteroat. Chem. 2000, 11, 380.
(7) Wu, J.; Liao, Y.; Yang, Z. J. Org. Chem. 2001, 66, 3642.
(8) Wu, J.; Yang, Z. J. Org. Chem. 2001, 66, 7875.
(9) Saleem, R.; Faizi, S.; Deeba, F.; Siddiqui, B. S.; Qazi, M. H.
Planta Med. 1997, 63, 454.
(10) Lin, G.-Q.; Hong, R. J. Org. Chem. 2001, 66, 2877.
(11) Pharkphoom, P.; Hiroshi, N.; Wanchai, D. E. Planta Med.
1998, 64, 774.
(12) Lei, J.-G.; Lin, G.-Q. Chin. J. Chem. 2002, 20, 1263.
(13) (a) Percec, V.; Bae, J.-Y.; Zhao, M.; Hill, D. H. J. Org.
Chem. 1995, 60, 176. (b) Percec, V.; Bae, J.-Y.; Hill, D. H.
J. Org. Chem. 1995, 60, 1060. (c) Percec, V.; Bae, J.-Y.;
Zhao, M.; Hill, D. H. J. Org. Chem. 1995, 60, 1066.
(d) Percec, V.; Golding, G. M.; Smidrkal, J.; Weichold, O. J.
Org. Chem. 2004, 69, 3447.
(14) General Procedure for the Synthesis of 7: To an oven-
dried Schlenk flask (25 mL) was charged 4-coumarin
compound 3 (0.5 mmol), NiCl2 (PPh3)2 (0.2 equiv), PPh3 (0.4
equiv), zinc dust (2.2 mmol) and dry toluene (3 mL) under
argon. The resulting mixture was heated to 90 °C. The aryl
halide 5 (0.6 mmol) was then added dropwise through
micro-syringe pump over 3 h. After the addition, the reaction
mixture was stirred at the same temperature until
completion. The reaction mixture was cooled down to r.t.,
quenched with 5% HCl and diluted by CH2Cl2. The mixture
was stirred vigorously at r.t. until the solution was clear. The
organic layer was separated and the water layer was
extracted with CH2Cl2 (3 × 10 mL). The combined organic
layer was washed with sat. aq NaHCO3, brine, and dried over
Na2SO4. The solution was concentrated under vacuum; the
obtained residue was purified by silica column chromato-
graphy to give the corresponding cross-coupling product 7
(selected characterization data of 7 are listed as follows).
(15) Compound 7c. 1H NMR (300 MHz, CDCl3): d = 9.69 (s, 1
H), 7.86 (m, 1 H), 7.54 (m, 1 H), 7.45 (m, 1 H), 7.22–7.16
(m, 2 H), 7.01 (m, 1 H), 6.40 (s, 1 H), 4.05 (s, 3 H), 3.70 (s,
3 H). MS (EI): m/z (%) = 310 (71) [M+], 295 (100). IR (KBr):
3088, 2947, 2837, 2733, 1729, 1695, 1683, 1604, 1584, 1566
cm–1. Anal. Calcd for C18H14O5: C, 69.67; H, 4.55. Found: C,
69.86; H, 4.57.
Acknowledgment
Financial support from the National Natural Science Foundation of
China (20172063 and 203900506), the Major State Basic Research
Development Program (G2000077506), and the Shanghai Munici-
pal Committee of Science and Technology is acknowledged.
References
(1) (a) Soine, T. O. J. Pharm. Sci. 1964, 53, 231. (b) Chen, C.
H.; Fox, J. L. Proc. Int. Conf. Lasers 1987, 995.
(c) Edelson, R. L. Sci. Am. 1988, August, 68. (d) Dini, A.;
Ramundo, E.; Saturnino, P.; Scimone, A.; Stagno
d’Alcontres, I. Boll. Soc. Ital. Biol. Sper. 1992, 68, 453.
(e) Hoult, J. R.; Paya, M. Gen. Pharmacol. 1996, 27, 713.
(f) Rocha, L.; Marston, A.; Kaplan, M.; Stoeckli-Evans, H.;
Thull, U.; Testa, B.; Hostettmann, K. Phytochemistry 1994,
36, 1381. (g) Levine, C.; Hiasa, H.; Marians, K. J. Biochim.
Biophys. Acta 1998, 29, 1400. (h) Vlietinck, A. J.; De
Bruyne, T.; Apers, S.; Pieters, L. A. Planta Med. 1998, 64,
97. (i) Murakami, A.; Gao, G.; Omura, M.; Yano, M.; Ito,
C.; Furukawa, H.; Takahashi, D.; Koshimizu, K.; Ohigashi,
H. Bioorg. Med. Chem. Lett. 2000, 10, 59. (j) Raboin, J.-C.;
Beley, M.; Kirsch, G. Tetrahedron Lett. 2000, 41, 1175.
(2) For reviews, see: (a) Egan, D.; Okennedy, R.; Moran, E.;
Cox, D.; Prosser, E.; Thornes, R. D. Drug Metab. Rev. 1990,
22, 503. (b) Pineo, G. F.; Hull, R. D. Drug Safety 1993, 9,
263. (c) Murray, R. D. H. Nat. Prod. Rep. 1995, 12, 477.
(d) Trivedi, K. N.; Rao, S. S. M.; Mistry, S. V.; Desai, S. M.
J. Indian Chem. Soc. 2001, 78, 579.
(3) (a) Awasthi, A. K.; Tewari, R. S. Synthesis 1986, 1061.
(b) Sato, K.; Inour, S.; Kobayashi, T.; Ota, T.; Tazaki, M. J.
Chem. Soc., Perkin Trans. 1 1987, 1753. (c) Desouza, M.
D.; Joshi, V. Indian J. Heterocycl. Chem. 1993, 3, 93.
(d) Ivanova, D. I.; Eremin, S. V.; Shvets, V. I. Tetrahedron
1996, 52, 9581. (e) Lee, Y. R.; Kim, B. S.; Wang, H. C.
Tetrahedron 1998, 54, 12215. (f) De la Hoz, A.; Moreno,
A.; Vazquez, E. Synlett 1999, 608. (g) Yavari, I.; Adib, M.;
Hojabri, L. Tetrahedron 2001, 57, 7537. (h) Gonzalez-
Gomez, J. C.; Santana, L.; Uriarte, E. Synthesis 2002, 43.
(i) Bose, D. S.; Rudradas, A. P.; Babu, M. H. Tetrahedron
(16) Compound 7f. 1H NMR (300 MHz, CDCl3): d = 8.08 (d,
J = 2.1 Hz, 1 H), 7.64 (s, 1 H), 7.54 (d, J = 7.5 Hz, 1 H), 7.51
(d, J = 7.5 Hz, 1 H), 7.42–7.21 (m, 4 H), 6.45 (d, J = 2.1 Hz,
1 H), 3.93 (s, 3 H). 13C NMR (75.5 MHz, CDCl3): d =
175.12, 160.67, 157.84, 154.08, 153.90, 151.45, 148.05,
132.41, 127.02, 124.91, 124.52, 120.90, 120.03, 118.95,
117.70, 117.45, 105.45, 56.28. MS (EI): m/z (%) = 320 (4)
[M+], 292 (10.00). IR (KBr): 3078, 2963, 1720, 1649, 1610,
1488, 1446, 1334, 1271 cm–1. HRMS: m/z calcd for
C19H12O5: 320.0685; found: 320.0734.
(17) Compound 7h. 1H NMR (300 MHz, CDCl3): d = 8.05 (s, 1
H), 7.65 (s, 1 H), 7.55–7.30 (m, 4 H), 7.11 (s, 1 H), 6.42 (s,
1 H), 3.94 (s, 3 H), 2.34 (s, 3 H). 13C NMR (75.5 MHz,
CDCl3): d = 174.84, 160.58, 157.73, 153.66, 151.79, 151.20,
147.65, 133.95, 133.21, 126.31, 124.64, 120.69, 119.76,
118.46, 117.47, 116.90, 105.26, 59.01, 20.91. MS (EI):
Synlett 2004, No. 13, 2364–2368 © Thieme Stuttgart · New York